The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.
L. C. Chen
Research Funding - ArQule
L. S. Rosen
Research Funding - ArQule
T. Iyengar
No relevant relationships to disclose
J. W. Goldman
Research Funding - ArQule
R. Savage
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
J. Kazakin
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
T. C. K. Chan
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
B. E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
G. Abbadessa
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
D. D. Von Hoff
Research Funding - ArQule